Discover how innovative physical therapy, smart medications, nutrition strategies and mind-body techniques are transforming ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Topline results were announced from a phase 3 trial evaluating cebranopadol for the treatment of moderate to severe acute pain in patients following ...

LTG-001 demonstrated rapid absorption with a Tmax of approximately 1.5 hours. The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain.

It is a nothingness many people with chronic pain are plunged into when their symptoms defy simple explanation. As a ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

The one-size-fits-all approach to pain management should be a thing of the past. But we’re still not there yet.

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...